Contract analysis

I. Purpose and Overview The purpose of this memorandum is to provide a contemporaneous summary of the in-person IRS Appeals conference held on Wednesday, February 28, 2024, at the IRS Appeals Office in Manhattan, New York, concerning the transfer pricing examination of Penterra Pharmaceuticals Corp. ("PPC") for tax years 2017, 2018, 2019, and 2020. This memorandum is prepared as attorney work product in anticipation

II. Conference Logistics A. Date, Time, and Location The conference was held on Wednesday, February 28, 2024, commencing at 10:00 a.m. and concluding at approximately 4:15 p.m. (Eastern Time). A lunch break was taken from approximately 12:30 p.m. to 1:30 p.m., during which the PPC team conferred privately in a separate conference room. The total substantive session time was approximately five hours and fifteen minute

III. Summary of Presentation and Discussion by Issue A. Opening Remarks and Case Overview Cross opened the conference by thanking Appeals Officer Castañeda for scheduling the in-person session and for her thorough preparation. Cross then provided an overview of PPC's corporate structure, which was essential context for the transfer pricing issues under examination. Corporate Structure. PPC is a Delaware corporation p

1. Cost-Sharing Arrangement (effective July 1, 2012): PPC and PBI entered into a qualified cost-sharing arrangement under Treas. Reg. § 1.482-7, pursuant to which the parties share the costs and risks of ongoing R&D activities in exchange for the right to exploit resulting intangible property in their respective territories (Americas for PPC; non-Americas for PBI). At the inception of the CSA, PBI made a platform con

2. Legacy IP Royalty Arrangement: For legacy pharmaceutical compounds (i.e., products that predated the CSA and were not subject to the cost-sharing arrangement), PBI pays PPC a royalty of 4.5% of net sales in non-Americas territories. These legacy compounds are in the declining phase of their product lifecycles. Contemporaneous Documentation. Cross emphasized that PPC maintained contemporaneous transfer pricing docu

1. PPC's Position as Presented Cross presented PPC's position on the CSA cost-sharing ratio, which constitutes the largest single component of the proposed adjustment. PPC's cost-sharing percentages for the four examination years were as follows: These percentages were determined based on reasonably anticipated benefits ("RAB") under Treas. Reg. § 1.482-7, reflecting PBI's projected share of the benefits from intangi

2. IRS Position (as Reflected in NOPA / Exam File) The IRS examination team asserted that PPC's RAB projections understated the value attributable to U.S.-source contributions and that the cost-sharing ratio should have been higher to reflect the concentration of PPC's R&D workforce and facilities in the United States. The examination team's position was that PPC's projected non-Americas revenues were overstated rela

3. Appeals Officer Castañeda's Questions and Reactions Appeals Officer Castañeda devoted substantial attention to the CSA cost-sharing ratio issue. She asked detailed and well-informed questions about how PPC determined the RAB split, focusing on three specific areas: (a) Revenue Metric. Castañeda asked which revenue metric was used in the RAB calculation — specifically, whether PPC used gross sales or net sales. Cro

1. PPC's Position as Presented Cross presented PPC's position on the legacy IP royalty rate, which is the second-largest component of the proposed adjustment. PPC charges PBI a royalty of 4.5% of net sales on legacy pharmaceutical compounds sold in non-Americas territories. These legacy compounds — products that predated the July 2012 CSA and are not subject to the cost-sharing arrangement — are in the declining phas

2. IRS Position (as Reflected in NOPA / Exam File) The IRS examination team proposed increasing the royalty rate from 4.5% to 11.0%, based on the IRS's own CUT analysis, which selected a different set of comparable license agreements. The IRS's comparable set included agreements that, in PPC's view, were not sufficiently comparable to the legacy IP license at issue. The resulting proposed additional royalty payments

3. Appeals Officer Castañeda's Questions and Reactions Castañeda devoted significant time to the CUT analysis, which appeared to be the issue of greatest analytical interest to her. She asked Dr. Vasquez to walk through the comparable selection criteria in detail, including the search methodology, the databases used, and the specific adjustments (if any) made to the comparable data. Castañeda's key questions focused

1. Discussion. Cross noted at the outset of the PCT discussion that tax year 2012 — the year in which the $312 million PCT payment was made — was outside the examination years (2017–2020). The IRS examination team did not propose a separate adjustment to the PCT payment itself. However, the IRS used the alleged undervaluation of the PCT to support its proposed adjustments to the ongoing CSA cost-sharing ratios and ro

2. Appeals Officer Castañeda's Questions and Reactions Castañeda asked pointed questions about the discount rate dispute, which she clearly understood to be the central valuation issue. She requested that Dr. Vasquez walk through the specific components of the WACC calculation, including the risk-free rate, equity risk premium, size premium, company-specific risk premium, beta, cost of debt, and capital structure ass

1. PPC's Position as Presented Cross and Whitfield presented a comprehensive package of evidence demonstrating PBI's economic substance and its meaningful performance of DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property). This issue was foundational to PPC's defense, as the IRS examination team's adjustments implicitly rested on the premise that PBI lacked suf

2. Appeals Officer Castañeda's Questions and Reactions Castañeda asked several probing but ultimately favorable questions on the economic substance issue: Dual Employment / Reporting Relationships. Castañeda asked whether any of PBI's 185 employees had dual employment arrangements or reporting relationships with PPC in the United States. This was a common question in transfer pricing examinations involving intercompa

1. PPC's Position as Presented Cross presented PPC's defense against the proposed IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million. PPC's defense rested on two principal grounds: Reasonable-Cause Defense. Under IRC § 6662(e)(3)(B), a taxpayer may avoid the substantial valuation misstatement penalty by demonstrating reasonable cause for, and good faith with respect to, the trans

2. Appeals Officer Castañeda's Questions and Reactions Castañeda asked two focused questions on the penalty issue: Timing of Documentation. Castañeda asked whether the contemporaneous documentation was prepared before or after the return filing deadline for each examination year. This was a critical threshold question, as the reasonable-cause defense under IRC § 6662(e)(3)(B) requires that the taxpayer maintain conte

IV. Correlative Offset and Interaction of Adjustments During the presentation, Cross addressed the $42.65 million correlative offset that the IRS examination team had allowed in the NOPA to avoid double-counting between the CSA cost-sharing ratio adjustment and the legacy IP royalty rate adjustment. Because both adjustments relate to payments between PPC and PBI — the CSA adjustment increases PBI's cost-sharing payme

V. Areas of Agreement Based on the totality of the conference proceedings, Appeals Officer Castañeda appeared to agree or largely concede on the following points:

1. PBI Economic Substance. PBI had sufficient economic substance to participate in the CSA and to serve as IP owner and licensee for non-Americas territories. The IRS examination team's implicit economic substance challenge is unlikely to be a significant factor in the settlement. Castañeda's questions on this topic were thorough but did not suggest any fundamental disagreement with PPC's position, and her favorable

2. IRC § 6662(e) Penalty. The IRC § 6662(e) substantial valuation misstatement penalty of $15.98 million should be abated. PPC's contemporaneous documentation and reasonable-cause defense were compelling, and Castañeda's statement that she was "inclined to not sustain the penalty" provides a clear indication of her intended resolution on this issue.

3. CUT Analysis Methodology. PPC's CUT analysis for the legacy IP royalty rate was methodologically sound and identified appropriate comparable license agreements. The IRS examination team's proposed 11.0% royalty rate was characterized by Castañeda as "well above" the interquartile range of PPC's comparable set, and she did not express any support for that rate. While Castañeda may seek a modest upward adjustment wi

4. PCT Valuation as Secondary Issue. The PCT valuation, while relevant as background context for the cost-sharing ratio analysis, was outside the examination years (2017–2020) and would not independently support a large adjustment for the years under examination. Castañeda treated this issue as secondary throughout the conference.

VI. Areas of Disagreement / Remaining Uncertainty The following areas remain unresolved and may be the primary focus of settlement negotiations in the coming weeks:

1. CSA Cost-Sharing Percentages. While Castañeda was clearly skeptical of the examination team's proposed 8–12 percentage point increases to PBI's cost-sharing ratio, she did not concede that PPC's cost-sharing percentages were entirely correct. Her questions about new product launch projections, retrospective testing, and the RAB methodology suggest that she may seek a modest upward adjustment to PBI's cost-sharing

2. Legacy IP Royalty Rate. Castañeda appeared to consider whether a royalty rate adjustment within the IQR of PPC's CUT analysis (above 4.5% but well below 11.0%) might be appropriate as a settlement position. Her question about whether a rate at the upper end of the IQR (6.8%) could be justified suggests she is exploring the range of potential settlement outcomes on this issue. Based on the tenor of her questions an

3. Correlative Offset Magnitude. The interaction between the CSA and royalty rate adjustments and the appropriate magnitude of the correlative offset under Treas. Reg. § 1.482-1(g) remains an open issue. Castañeda acknowledged the overlap but did not indicate her position on the appropriate offset calculation. This issue could have a meaningful impact on the net settlement amount.

4. Year-by-Year Allocation of Settlement Adjustment. Castañeda did not discuss the methodology for allocating any agreed-upon settlement adjustment across the four examination years (2017–2020). This will need to be addressed in the settlement negotiations, as the year-by-year allocation affects the computation of interest and potentially other considerations.

VII. Overall Assessment and Settlement Trajectory The February 28, 2024 Appeals conference was constructive and professional throughout. Appeals Officer Castañeda was well-prepared, having thoroughly reviewed the full case file, the Formal Protest, the supporting exhibits, the examination team's RAR, and the IRS economist's analysis. Her questions were probing but fair, and she demonstrated a strong understanding of

VIII. Supplemental Submission Requested During the conference, Appeals Officer Castañeda requested that PPC provide supplemental information to assist her in completing her analysis. The specific items requested were:

1. Additional Comparable License Agreements. Castañeda asked PPC to identify any additional comparable license agreements that may have been entered into since the Whitmore CUT analysis was finalized, particularly any pharmaceutical license agreements from 2023 that had come to market and might be relevant to the arm's-length range for the legacy IP royalty rate.

2. Updated CPM/TNMM Benchmarking Data. Castañeda asked whether updated benchmarking data was available for the CPM/TNMM analysis, including any additional comparable company financial data that may have become available since the original analysis was prepared.

3. RAB Methodology Clarifications. Castañeda requested a brief written response to certain specific questions about the RAB methodology used to determine the CSA cost-sharing percentages, particularly relating to the methodology for projecting new product launches in non-Americas markets and the assumptions underlying those projections. Cross agreed to provide this supplemental submission within 10 days of the confer

IX. Next Steps The following action items should be completed in connection with the post-conference follow-up:

1. Supplemental Submission. Simmons and Dr. Vasquez to prepare and finalize the supplemental written submission to Appeals Officer Castañeda, addressing the three categories of supplemental information requested during the conference. Target submission date: March 8, 2024. Simmons to coordinate with Whitmore to begin the updated comparable search and CPM/TNMM data refresh immediately. Cross and Hartwell to review and

2. Client Debrief. Cross to debrief Marcus Whitfield (VP of Global Tax), Deborah Staines (General Counsel), and Rajesh Iyer on the conference results. The debrief will take the form of an email summary followed by a detailed follow-up call. Cross's debrief email is to go out today, March 1, 2024. The follow-up call should be scheduled within the next several business days to discuss the conference results in detail a

3. Settlement Preparation. Continue refining the sensitivity analysis of settlement ranges based on the insights gained from the conference. Simmons to update the settlement range model, incorporating the conference dynamics and Castañeda's apparent positions, with a focus on the 10%–15% target range. The model should include scenarios for varying CSA cost-sharing percentage adjustments (1–3 percentage points), royal

4. Await Settlement Offer. Castañeda indicated that a written settlement proposal would follow "within the next few weeks." The team should be prepared to analyze and respond promptly upon receipt. Simmons to monitor for incoming correspondence from Appeals and to circulate any settlement proposal immediately upon receipt.

5. FIN 48 / ASC 740-10 Considerations. Following receipt of the settlement offer, the FIN 48 / ASC 740-10 uncertain tax position reserve analysis will need to be updated. PPC's current reserve stands at $62.4 million, which was established based on the full NOPA amount. The reserve will need to be adjusted downward if, as expected, the settlement is reached at a significantly lower amount. Simmons to coordinate with